UBS raises Gilead Sciences stock price target on HIV strength
UBS raises Gilead Sciences stock price target on HIV strength Investing.com
Covered in this story
Analyst targets on Gilead Sciences
- Bank of America: $157 → $172 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $GILD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Gilead Sciences →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.